US Patents
GRANTED US PATENTS
1. Orhan, M. D., Avsar, T., Dogan, B., Cacan, G., Calis, S., & Durdagi, S. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-1), (U.S. Patent No. 12,384,746 B2). U.S. Patent and Trademark Office.
2. Dogan, B., Durdagi, S., Cacan, G., Calis, S., Avsar, T., & Orhan, M. D. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-2), (U.S. Patent No. 12,318,368 B2). U.S. Patent and Trademark Office
3. Orhan, M. D., Dogan, B., Calis, S., Cacan, G., Avsar, T., & Durdagi, S. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-4), (U.S. Patent No. 12,297,175 B2). U.S. Patent and Trademark Office.
4. Sensoy, Ö., Güzel, M., Kerman, B. E., Üstündağ Okur, N., Mansoor, S., Hanashalshahaby, E., Keskin, E., Durdagi, S., & Kayık, G. (2021). Heterobivalent ligands suitable for use in the treatment of Parkinson’s disease (U.S. Patent No. 11,053,270 B2). U.S. Patent and Trademark Office.
GRANTED US PATENTS
1. Orhan, M. D., Avsar, T., Dogan, B., Cacan, G., Calis, S., & Durdagi, S. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-1), (U.S. Patent No. 12,384,746 B2). U.S. Patent and Trademark Office.
2. Dogan, B., Durdagi, S., Cacan, G., Calis, S., Avsar, T., & Orhan, M. D. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-2), (U.S. Patent No. 12,318,368 B2). U.S. Patent and Trademark Office
3. Orhan, M. D., Dogan, B., Calis, S., Cacan, G., Avsar, T., & Durdagi, S. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-4), (U.S. Patent No. 12,297,175 B2). U.S. Patent and Trademark Office.
4. Sensoy, Ö., Güzel, M., Kerman, B. E., Üstündağ Okur, N., Mansoor, S., Hanashalshahaby, E., Keskin, E., Durdagi, S., & Kayık, G. (2021). Heterobivalent ligands suitable for use in the treatment of Parkinson’s disease (U.S. Patent No. 11,053,270 B2). U.S. Patent and Trademark Office.